Spyre Therapeutics Shares Rise 4% Following Completion Of Enrollment In SKYWAY Phase 2 Trial
Spyre Therapeutics’ (SYRE) shares rose 4.16% to $72.04 on Wednesday after the company said enrollment was completed across all sub-studies in its SKYWAY Phase 2 basket trial of SPY072, an anti-TL1A therapy for rheumatic diseases. The company said enrollment finished in under nine months and keeps it on track for five of six Phase 2 data readouts in 2026.
How this was made
The 30-second read
Why it matters
By completing enrollment in under nine months, Spyre reduces execution uncertainty and reinforces management’s plan to deliver five of six Phase 2 data readouts in 2026.
Market read
Traders are likely to re-rate the probability of timely upcoming Phase 2 catalysts, driving a positive near-term reaction.
What to watch
The article doesn’t provide interim results, effect sizes, or safety signals—future volatility likely hinges on the next specific Phase 2 readouts in 2026.
Background
SKYWAY is a Phase 2 basket trial evaluating SPY072, an investigational anti-TL1A therapy, across rheumatic diseases including RA, PsA, and axSpA.
Ticker impact
Spyre Therapeutics completed enrollment across all SKYWAY Phase 2 sub-studies for SPY072, keeping 2026 Phase 2 readouts on track.
Near-term upside bias versus peers/benchmarks as traders price in improved probability of upcoming readouts.
The article reports a concrete clinical milestone (enrollment completion) and links it to planned 2026 data timing, which typically moves biotech sentiment and expectations.
Market effects
Supports risk-on sentiment for small/mid-cap biotech running Phase 2 basket trials in rheumatology targeting TL1A.
Primarily US small-cap biotech sentiment; limited broader regional spillover implied.
Modest—clinical execution milestone for a single investigational therapy with no stated global regulatory action.
Counterpoint
Enrollment completion can be necessary but not sufficient; without efficacy/safety readouts, the move may fade if upcoming data disappoint.
Key entities
- companySpyre Therapeutics
Clinical-stage biotech; announced enrollment completion in its SKYWAY Phase 2 basket trial for SPY072.
- drug_candidateSPY072
Investigational anti-TL1A therapy being evaluated in the SKYWAY Phase 2 trial.
- clinical_trialSKYWAY Phase 2 basket trial
Phase 2 program with multiple sub-studies across rheumatic diseases; enrollment completion is the reported milestone.
